01 December
A webinar outlining the implications of the changing regulatory landscape on the industry in the short to medium term - and what could be considered in developing strategies to increase the safety profile of products - is being hosted by ICON on Wednesday 9 December at 4 pm GMT. 'Politics, Regulators and Clinical Research' will feature panelists including ICON's Suzanne Gagnon, IMS Health's Nigel Burrows and Christopher-Paul Milne, associate director of the Tufts Center for the Study of Drug Development.
Senior pharma executives involved in the drug safety or/and outsourcing strategies for their organization are invited to attend the webinar, which will discuss "what the political reforms of today mean for clinical research tomorrow"; "how recently published draft regulations from the FDA (and the expected EMEA guidelines) address drug safety and what they mean for your organization"; and "what innovative strategies pharma/biotech companies can do to continue to deliver treatments in a cost effective way."
Click here to register for this event.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.